{"id":4416,"date":"2019-03-26T05:08:03","date_gmt":"2019-03-26T05:08:03","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?post_type=study_trials&#038;p=4416"},"modified":"2019-11-12T15:29:51","modified_gmt":"2019-11-12T15:29:51","slug":"everolimus-and-anakinra-or-denosumab-in-treating-participants-with-relapsed-or-refractory-advanced-cancers","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/de\/study_trials\/everolimus-and-anakinra-or-denosumab-in-treating-participants-with-relapsed-or-refractory-advanced-cancers\/","title":{"rendered":"Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers"},"content":{"rendered":"<p><strong>Ziel der Studie:&nbsp;<\/strong>&nbsp;The goal of this Phase I clinical research study is to determine the tolerable dose of the combination of Afinitor (everolimus) either with Kineret (anakinra) or Xgeva (denosumab) for patients with advanced cancer.&nbsp; Everolimus is designed to stop cells from dividing.&nbsp; Anakinra is designated to block a protein that is involved in tumor development, new blood vessels growing, and spread of cancer.&nbsp; Denosumab is designed to block the activity of a protein, which may prevent bone complications in cancer that has spread to the bone.<br \/>\n<strong>Sponsor:&nbsp;&nbsp;<\/strong>M.D. Anderson Cancer Center<br \/>\n<strong>Kontaktdaten f\u00fcr die Testphase:&nbsp;&nbsp;<\/strong>Veronica Holley; VRHolley@mdanderson.org Filip Janku; 713-563-1930; FJanku@mdanderson.org<br \/>\n<strong>Gew\u00fcnschte Einbeziehung des Patienten:&nbsp;&nbsp;<\/strong>ECD patients at least 18 years of age.&nbsp; Patients may be BRAF positive or negative.<br \/>\n<strong>Bekannte Zentren, die ECD-Patienten in die Studie aufnehmen:&nbsp;<\/strong>&nbsp;MD Anderson, Houston, Texas<br \/>\n<strong>ClinicalTrials.gov-Kennung:<\/strong>&nbsp; NCT01624766<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective:&nbsp;&nbsp;The goal of this Phase I clinical research study is to determine the tolerable dose of the combination of Afinitor (everolimus) either with Kineret (anakinra) or Xgeva (denosumab) for [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[32],"class_list":["post-4416","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-drug-trial"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/de\/wp-json\/wp\/v2\/study_trials\/4416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/de\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/de\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/de\/wp-json\/wp\/v2\/media?parent=4416"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/de\/wp-json\/wp\/v2\/study_trials_cat?post=4416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}